The Open University's first one-day symposium on treatment-emergent neuroendocrine prostate cancer.
cancer biomarkers
epigenetics
long noncoding RNAs
neuroendocrine prostate cancer
osteopontin
tumor microenvironment
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
pubmed:
23
1
2020
medline:
7
10
2020
entrez:
23
1
2020
Statut:
ppublish
Résumé
The Open University's first one-day symposium on treatment-emergent neuroendocrine prostate cancer attracted world-leading figures, early career researchers and industry colleagues. The symposium proved insightful into the 'real-world' impact and current problems faced in the diagnosis and treatment of neuroendocrine prostate cancer. It was important for this meeting to take place as the incidence of neuroendocrine prostate cancer is increasing due to the widespread use of next-generation androgen deprivation drugs. The symposium discussions proposed new molecularly driven deadlines to accelerate research and improved the treatment of this deadly and poorly recognized malignancy.
Identifiants
pubmed: 31964195
doi: 10.2217/fon-2019-0718
doi:
Substances chimiques
Androgen Antagonists
0
Biomarkers, Tumor
0
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM